Incyte (INCY) Set to Announce Quarterly Earnings on Tuesday

Incyte (NASDAQ:INCY) will be issuing its quarterly earnings data before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.88 per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Incyte (NASDAQ:INCY) last issued its quarterly earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.09). Incyte had a net margin of 16.17% and a return on equity of 12.56%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the company posted $0.44 EPS. The business’s revenue was up 9.3% compared to the same quarter last year. On average, analysts expect Incyte to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Incyte Trading Up 1.0 %

INCY opened at $51.68 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.55 and a quick ratio of 3.36. Incyte has a fifty-two week low of $50.27 and a fifty-two week high of $75.74. The firm has a market capitalization of $11.60 billion, a PE ratio of 19.50, a P/E/G ratio of 1.18 and a beta of 0.65. The company’s 50-day moving average is $56.78 and its 200 day moving average is $57.70.

Analyst Upgrades and Downgrades

INCY has been the subject of a number of research reports. Oppenheimer reduced their target price on shares of Incyte from $92.00 to $84.00 and set an “outperform” rating for the company in a research report on Wednesday. Bank of America lowered their price objective on shares of Incyte from $69.00 to $67.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 13th. Jefferies Financial Group initiated coverage on shares of Incyte in a research report on Friday, February 23rd. They set a “buy” rating and a $81.00 price objective on the stock. Cantor Fitzgerald initiated coverage on shares of Incyte in a research report on Tuesday, April 23rd. They issued a “neutral” rating on the stock. Finally, Truist Financial decreased their target price on shares of Incyte from $91.00 to $84.00 and set a “buy” rating on the stock in a research report on Wednesday, February 14th. Nine equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $75.50.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.